What Outcomes From Pharmacologic Treatments Are Important to People With Rheumatoid Arthritis? Creating the Basis of a Patient Core Set
What Outcomes From Pharmacologic Treatments Are Important to People With Rheumatoid Arthritis? Creating the Basis of a Patient Core Set
复制标题
DOI：
10.1002/acr.20034
复制
发表时间：
2010-05-01
影响因子：
4.7
通讯作者：
Hewlett, S.
中科院分区：
文献类型：
--
作者：
Sanderson, T.;Morris, M.;Hewlett, S.
客观的。在类风湿性关节炎 (RA) 临床试验中常规测量功能、患者整体评估和疼痛。然而，在定性研究中被认为对患者重要的其他患者报告的结果（例如疲劳和生活质量）通常不包括在内，并且现代治疗方案可能改变了患者对治疗结果的期望。我们的目标是自抗肿瘤坏死因子（抗 TNF）治疗的普遍使用以来，引出患者优先进行药物干预的治疗结果，这将构成患者优先事项核心组的基础，以补充现有的专业核心组。方法。对 23 名 RA 患者进行了深入访谈，有目的地抽取年龄、性别、药物（抗 TNF 或其他缓解疾病的抗风湿药物）、疾病严重程度和工作状态。扎根理论指导迭代数据收集和分析。数据编码经过同行评审。患者研究伙伴合作进行研究设计和分析。结果。访谈产生了 63 种对患者重要的不同结果。药物治疗的患者结果分为四个主要类别：“RA 得到控制”、“做事”、“情绪健康”和“应对疾病”。核心类别（或总体主题）是“尽量减少 RA 对个人的影响”。结论。尽管患者提高了疼痛、功能和整体健康等常规结果，但他们还从治疗中产生了另外 60 种重要结果。这种观点的差异可能会影响治疗决策。因此，下一步是使用这些数据来开发患者核心集。
Objective. Function, patient global assessment, and pain are routinely measured in rheumatoid arthritis (RA) clinical trials. However, other patient-reported outcomes identified as important to patients in qualitative studies, such as fatigue and quality of life, are commonly not included, and modern treatment regimens may have changed patients' expectations of treatment outcomes. Our objective was to elicit patient priority treatment outcomes for pharmacologic interventions since the common use of anti-tumor necrosis factor (anti-TNF) therapy, which will form the basis of a core set of patient priorities to complement existing professional core sets.Methods. In-depth interviews were conducted with 23 RA patients, purposively sampled for age, sex, medication (anti-TNF or other disease-modifying antirheumatic drugs), disease severity, and work status. Grounded theory guided iterative data collection and analysis. Coding of the data was peer reviewed. A patient research partner collaborated in the research design and analysis.Results. Sixty-three different outcomes important to patients were generated from the interviews. Four major categories of patient outcomes from pharmacologic treatments were developed: "RA under control," "Doing things," "Emotional health," and "Coping with illness."The core category (or overall theme) was " Minimizing the personal impact of RA."Conclusion. Although the routine outcomes of pain, function, and overall well-being were raised by the patients, they also generated a further 60 important outcomes that they look for from treatment. This difference in perspective may potentially influence treatment decisions. The next step is therefore to use these data to develop a patient core set.